Percutaneous Removal and Margin Ablation for Breast Cancer

Using the Mammotome Breast Biopsy System (IVEB) in conjunction with MRI to predict extent of disease, ultrasound to direct removal of the tumor, touch preparation cytology for diagnosis, and ablation of margins using radiofrequency ablation (RFA), we propose to develop a comprehensive system for same-day diagnosis and treatment of patients with small breast lesions.

Inclusion criteria

• Female, 18 to 90 years of age
• Non-pregnant, not breastfeeding
• Pre-study documentation of:
• Size ≤1.5 cm cancer successfully removed by US-guided IVEB within 30 days of registration
• Uni-centricity, unilateral cancer by radiology (mammogram and MRI)
• Location of abnormality > 1 cm from the skin
• Ductal Carcinoma, Invasive (Grade I-III) or In-Situ
• No palpable axillary or supraclavicular lymph nodes
• Good general health
• Zubrod Performance Status of 0, 1, or 2
• If prior non-breast malignancy, must have 5 year disease-free survival
• No prior chemotherapy
• Hormonal therapy must be stopped
• Therapy with tamoxifen must have been of 14 days or less duration

Exclusion criteria

• Subjects less than 18 years of age or greater than 90 years of age
• Pregnant or breastfeeding
• Male
• Prior Breast Biopsy affected breast
• Breast implants
• Multicentric disease, bilateral disease
• Residual disease after IVEB of > 1cm on MRI
• Lesions > 1.5 cm in diameter
• Lesions < 1 cm from skin surface
• Previous radiation therapy to the breast